Moderna Promises Revenue Growth In 2026, Even As FDA Flu Vaccine Setback Looms

Moderna Inc. (NASDAQ:MRNA) on Friday reported a fourth-quarter loss of $2.11, beating the expected loss of $2.59, lower than a loss of $2.91 a year ago.The COVID-19 vaccine maker reported quarterly sales of $678 million, topping the expected $626.097 million.Total revenue was on the higher end of the company's prior expectations and was driven primarily by COVID vaccine sales.Product sales were $264 million in the U.S. and $381 million in international markets. Fourth quarter revenue decreased 30% year over ...